



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/004,633	12/04/2001	Douglas Adam Levinson	7853-251-999	8471

20583 7590 12/03/2003
PENNIE AND EDMONDS
1155 AVENUE OF THE AMERICAS
NEW YORK, NY 100362711

EXAMINER

SWARTZ, RODNEY P

ART UNIT	PAPER NUMBER
----------	--------------

1645

DATE MAILED: 12/03/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/004,633

Applicant(s)

LEVINSON ET AL.

Examiner

Rodney P. Swartz, Ph.D.

Art Unit

1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 4September2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-21 is/are pending in the application.
- 4a) Of the above claim(s) 1,2 and 12-16 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 3-11 and 17-21 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-21 are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
- a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 1.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

Art Unit: 1645

DETAILED ACTION

1. Applicants' Response to Restriction, received 4 September 2003, paper #9, is acknowledged.

Applicants elect, without traverse, Invention III, claims 3-11 and 17-21, drawn to a method of treatment of ischemic disorder by giving an antibody, classified in class 530, subclass 387.1. Claims 1, 2, and 12-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention.

Applicants also elect, without traverse, ischemic renal disease under the species election requirement.

2. Claims 3-11 and 17-21, drawn to a method of treatment of ischemic disorder by giving an antibody, are under consideration.

Drawings

3. This application was submitted with informal drawings which are acceptable for examination purposes only. When the application is allowed, applicant will be required to submit new formal drawings.

Specification

4. The disclosure is objected to because of the following informalities:

Page 209, line 26, "referfusion" should be "reperfusion"; line 27, "is" should be "in",

Appropriate correction is required.

Claim Rejections - 35 USC § 112

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Art Unit: 1645

6. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7. Claims 3-11 and 17-21 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Claims 3-11 and 17-21 are drawn to a method for ameliorating a symptom of an ischemic disorder or injury in a mammal, comprising administering to the mammal an antibody directed against a 200 gene product in an amount effective to ameliorate the symptom of the disorder.

However, the example provided in the instant specification, i.e., Example 13, pages 206-211, teach the exact opposite. Mice, which had kidney ischemia induced, as well as sham treated mice, received injections of either rat Ig (RtIg) antibody or a specific anti-200 gene product monoclonal rat antibody (laboratory designation 96.3.8H7 mAb). Kidney histology and serum creatinine and urea nitrogen levels were analyzed. As stated on page 210: "Creatinine and blood urea nitrogen levels returned to basal levels in **untreated** (+RtIg) mice within 72 hours post ischemia. However, mice treated with anti-200 mAb (+a200) maintained **elevated** levels of **both** blood urea nitrogen (122.5 mg/dl vs. 34.3 mg/dl) and creatinine (0.73 mg/dl vs. 0.3 mg/dl)." (emphasis added by examiner). As stated on page 211: "In summary, these results provide *in vivo* animal data demonstrating that **the 200 gene product plays a critical role as a novel treatment** to aid in the recovery from ischemic injuries such as acute renal failure." (emphasis added by examiner). Therefore, **applicants' wn example show the exact opposite effect** to that which is claimed, i.e., treatment with a monoclonal antibody

Art Unit: 1645

directed against a 200 gene product ameliorates symptom of an ischemic disorder or injury, in that treatment with the monoclonal antibody exacerbates and prolongs the ischemic disorder or injury as evidenced by the elevated levels of serum creatinine and blood urea nitrogen in mice treated with the monoclonal antibody.

8. Claims 4-11 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claims are dependent from nonelected claims, i.e., claims 1 and 2, and therefore are indefinite.

Deposit Requirement

The specification lacks complete deposit information for the deposit of rat monoclonal antibody, designated designation 96.3.8H7 mAb. Because it is not clear that any other monoclonal antibody possessing the properties of 96.3.8H7 mAb are known and publicly available or can be reproducibly isolated from nature without undue experimentation and because the best mode disclosed by the specification requires the use of 96.3.8H7 mAb, a suitable deposit for patent purposes is required. Without a publicly available deposit of the above monoclonal antibody designated 96.3.8H7 mAb, one of skill in the art could not be assured of the ability to practice the invention as claimed. Exact replication of the monoclonal antibody designated 96.3.8H7 mAb is an unpredictable event. Note that the best mode is not satisfied by a written disclosure unless the exact embodiment is reasonably reproducible from that disclosure. If reproducibility of the monoclonal antibody designated 96.3.8H7 mAb is not established, failure to deposit monoclonal antibody designated 96.3.8H7 mAb would result in

Art Unit: 1645

concealment of the best mode contemplated by applicant for carrying out the invention. In re Sherwood, 615.2d 809, 204 USPQ 537 (CCPA 1980).

If the deposit has been made under the provisions of the Budapest Treaty, filing of an affidavit or declaration by applicant or assignees or a statement by an attorney of record who has authority and control over the conditions of deposit over his or her signature and registration number stating that the deposit has been accepted by an International Depository Authority under the provisions of the Budapest treaty, that all restrictions upon public access to the deposit will be irrevocably removed upon the grant of a patent on this application and that the deposit will be replaced if viable samples cannot be dispensed by the depository is required. This requirement is necessary when deposits are made under the provisions of the Budapest Treaty as the Treaty leaves this specific matter to the discretion of each nation. Amendment of the specification to recite the date of deposit and the complete name and full street address of the depository is required.

If the deposits have not been made under the provisions of the Budapest treaty, then in order to certify that the deposits comply with the criteria set forth in 37 CFR §§1.801-1.809, assurances regarding availability and permanency of deposits are required. Such assurance may be in the form of an affidavit or declaration by applicants or assignees or in the form of a statement by an attorney of record who has the authority and control over the conditions of deposit over his or her signature and registration number averring:

- a) during the pendency of this application, access to the deposits will be afforded to the Commissioner upon request;
- b) all restrictions upon the availability to the public of the deposited biological material will be irrevocably removed upon the granting of a patent on this application;

Art Unit: 1645

c) the deposits will be maintained in a public depository for a period of at least thirty years from the date of deposit or for the enforceable life of the patent or for a period of five years after the date of the most recent request for the furnishing of a sample of the deposited biological material, whichever is longest; and

d) the deposits will be replaced if they should become nonviable or non-replicable.

In addition, a deposit of biological material that is capable of self-replication either directly or indirectly must be viable at the time of deposit and during the term of deposit. Viability may be tested by the depository. The test must conclude only that the deposited material is capable of reproduction. A viability statement for each deposit of a biological material not made under the Budapest Treaty must be filed in the application and must contain:

- 1) the name and address of the depository,
- 2) the name and address of the depositor,
- 3) the date of deposit,
- 4) the identity of the deposit and the accession number given by the depository,
- 5) the date of the viability test,
- 6) the procedures used to obtain a sample if the test is not done by the depository, and
- 7) a statement that the deposit is capable of reproduction.

As a possible means for completing the record, applicant may submit a copy of the contract with the depository for deposit and maintenance of each deposit.

If the deposit was made after the effective filing date of the application for patent in the United States, a verified statement is required from a person in a position to corroborate that

Art Unit: 1645

the ----- described in the specification as filed is the same as that deposited in the depository. Corroboration may take the form of a showing of a chain of custody from applicant to the depository coupled with corroboration that the deposit is identical to the biological material described in the specification and in the applicant's possession at the time the application was filed.

Applicant's attention is directed to *In re Lundeck*, 773 F.2d. 1216, 227 USPQ 90 (CAFC 1985) and 37 CFR §§1.801-1.809 for further information concerning deposit practice.

Conclusion


9. No claims are allowed.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rodney P. Swartz, Ph.D., whose telephone number is (703) 308-4244.

The examiner can normally be reached on Monday through Thursday from 5:30 AM to 4:00 PM EST.

If attempts to reach the Examiner by telephone are unsuccessful, the examiner's supervisor, Lynette F. Smith, can be reached on (703)308-3909. The facsimile telephone number for the Art Unit Group is (703) 872-9306

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist whose telephone number is (703)308-2035.


RODNEY P SWARTZ, PH.D
PRIMARY EXAMINER
Art Unit 1645

December 1, 2003